At LifeStrands Genomics, we are always at the forefront of innovation in genomics and proteomics. We are thrilled to announce a groundbreaking development in the field of spatial proteomics – the launch of the GeoMx IO Proteome Atlas (IPA) by NanoString Technologies.
Pioneering Spatial Proteomics
GeoMx IPA is set to revolutionize how researchers perceive and analyze cellular biology. Developed by NanoString Technologies, a pioneer in life science tools for discovery and translational research, this new assay for the GeoMx® Digital Spatial Profiler (DSP) opens up unprecedented possibilities. GeoMx IPA enables the spatial profiling of more than 500 immuno-oncology (IO) relevant targets in Formalin-Fixed, Paraffin-Embedded (FFPE) tissue sections.
What sets this assay apart is its exclusive use of IHC-validated antibodies from abcam’s extensive IO portfolio. This collaboration marks a significant milestone in the field of spatial proteomics. GeoMx IPA provides researchers with more than five times the content of competing panels, delivering unparalleled depth and breadth of data. This wealth of information is a game-changer for research endeavors, from identifying novel biomarkers and drug targets to deciphering therapeutic responses, patient stratification, and unraveling drug mechanisms of action.
A Fusion of Cutting-Edge Fields
Brad Gray, President and CEO of NanoString, rightly describes GeoMx IPA as the convergence of two dynamic fields in biomedical research: spatial biology and high-plex proteomics. With abcam’s top-notch IO antibodies incorporated into a single assay, researchers gain access to a powerful tool that combines spatial profiling with high-quality reagents. When GeoMx IPA is combined with our popular Whole Transcriptome Atlas (WTA), GeoMx DSP emerges as the most potent spatial profiler available.
Unprecedented Data Unveiled
The combination of LifeStrands Genomics’ GeoMx IPA and WTA offers researchers an unmatched wealth of data within the largest-ever spatial proteomic panel of its kind. Capitalizing on GeoMx DSP’s unique capabilities, researchers can quantitatively profile protein expression over a vast dynamic range in distinct tissue compartments, such as tumors, stroma, and the immune contexture. GeoMx IPA can be employed as a standalone assay or in tandem with GeoMx WTA, and the data from both assays can be seamlessly integrated for comprehensive analysis.
Alejandra Solache, SVP of R&D at abcam, echoes our excitement about this collaboration, emphasizing the opportunity to contribute abcam’s precision antibodies to the GeoMx IO Proteome Atlas. This partnership promises to accelerate novel discoveries and enhance our understanding of cancer immunology.
Beyond Cancer Research
While initially tailored for IO research, GeoMx IPA holds vast applicability across diverse research domains, including infectious diseases, organ transplantation, autoimmunity, metabolism, and epigenetics. This broad scope reflects the potential of this technology to impact various scientific endeavors positively.
Researchers at LifeStrands Genomics now have the power to:
- Spatially Profile FFPE Tissue: Utilize over 500 IHC-validated IO antibodies from abcam in a single assay, simplifying the quest for new protein biomarkers and drug targets.
- Access Comprehensive Insights: Obtain deeper biological insights from precious tissue samples compared to conventional immunohistochemistry (IHC) or immunofluorescence (IF) assays.
- Discover Novel IO Drug Targets: Profile the expression of over 500 protein targets from a single FFPE tissue section, fostering the discovery of innovative IO drug targets.
- Combine with GeoMx WTA: Profile the entire human transcriptome and IO proteome from a single slide by pairing GeoMx IPA with GeoMx WTA, enabling spatial proteogenomic analysis on the same slide.
We are thrilled to announce that GeoMx IPA is available now for pre-order, with shipments expected to commence in Q4 2023. This revolutionary technology promises to empower our researchers at LifeStrands Genomics and the broader scientific community, propelling us into a new era of biological research. Join us on this exciting journey towards innovation and discovery, and stay tuned for more updates as we explore the endless possibilities of spatial proteomics.